Ebola Treatment

• NanoViricides, Inc. (NYSE American: NNVC) announced on August 18, 2026, that it will soon begin a Phase II clinical trial for NV-387 oral gummies. • The trial aims to treat the Bundibugyo Ebola virus during what is described as the largest and most rapidly expanding outbreak to date in the Democratic Republic of Congo. • This development is critical as the company seeks to provide an accessible, antiviral treatment that prevents viral escape during a major public health crisis.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies to treat Ebola in the Democratic Republic of Congo. • The trial aims to combat the current outbreak, which is described as the largest and most expanding in the region's history. • Led by Professor Katoto and supported by experts like Fogarty Fellow Patrick, the study leverages specialized implementation research networks to scale novel treatments.

• NanoViricides, Inc. (NYSE American: NNVC) received regulatory approval on August 10, 2026, to launch a Phase II clinical trial for its NV-387 oral gummies. • The trial will take place in the Democratic Republic of Congo to treat patients affected by the current largest and most rapidly expanding Ebola outbreak. • This development is critical as the company aims to provide an accessible, antiviral treatment designed to prevent viral escape during a public health crisis.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies, designed as a treatment for the Ebola virus. • The trial will take place in the Democratic Republic of Congo to combat the largest and most rapidly expanding Ebola outbreak on record. • The urgency for the treatment is heightened by the virus spreading into displacement camps housing over 4.4 million people, where poor sanitation and medical resources increase risk.

Aid worker flown to Berlin as Trump administration bars Americans from traveling to US on commercial flightsA US national who contracted Ebola in the Democratic Republic of the Congo has arrived in Germany for treatment, the health ministry in Berlin said on Monday, weeks after another American infected with Ebola in the DRC was treated in Berlin.Meanwhile, the Trump administration on Monday said it was blocking American citizens in ⁠the DRC from traveling to the US on commercial flights, Reuters reported, citing a White House official. Continue reading...

• The first patients have been enrolled in a record-breaking clinical trial for two potential Ebola drugs in the Ituri region of the Democratic Republic of the Congo. • The research program was launched with unprecedented speed, beginning just six weeks after the WHO declared the outbreak a public health emergency on May 17. • This trial is critical because there are currently no approved drugs available to help medical teams treat patients and reduce mortality rates during the outbreak.

Two drugs are being trialled in the Ituri region in a programme set up just six weeks after the outbreak was declared, with hopes it will reduce mortality ratesThere is no approved drug to help the medical teams scrabbling to save lives in the Ebola outbreak in the Democratic Republic of the Congo – but there are hopes that could change within months as the first patients are enrolled in a treatment trial.It is a record pace to set up and start this kind of research, scientists said, with patients enrolled just six weeks after the outbreak being declared a public health emergency of international concern by the World Health Organization (WHO) on 17 May. Continue reading...

• The World Health Organization (WHO) has launched participant enrollment for the PARTNERS clinical trial to investigate targeted treatments for the Bundibugyo virus. • This specific strain of the Ebola virus is responsible for the current outbreak, yet there are currently no approved preventive vaccines or targeted treatments available. • The trial is a collaborative effort coordinated by the University of Oxford, the Institute of Tropical Medicine in Belgium, and the Africa Centres for Disease Control and Prevention (Africa CDC).

• The Democratic Republic of the Congo (DRC) is currently battling an Ebola outbreak caused by a viral strain for which no specific treatments or preventive measures currently exist. • To address this medical gap, three new clinical trials have been launched to test potential breakthroughs in treating and preventing the virus. • These trials are critical because the lack of targeted therapies increases the risk of mortality and complicates efforts to contain the spread of the disease.

• The World Health Organization (WHO) has launched the first-ever clinical trial to test treatments against the Ebola Bundibugyo virus in the Democratic Republic of the Congo (DRC). • The study will evaluate the efficacy of an antiviral drug and an antibody cocktail, with the first patient already enrolled in a trial that could include up to 1,200 participants. • This initiative is critical for taming the burgeoning outbreak in the DRC, specifically targeting the Bundibugyo strain to reduce mortality and transmission.